Teva inks $200M global licensing deal with migraine rival Alder
Teva has struck a deal with rival migraine drug maker Alder BioPharmaceuticals, giving Alder a global license for eptinezumab for up to $200 million in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
